The FDA last week approved Teva Pharmaceuticals’ Cassipa buprenorphine and naloxone sublingual film as a maintenance treatment for opioid dependence.
There are a number of brand name and generic versions of buprenorphine and naloxone therapies that are delivered via a sublingual film. Teva’s product contains 16 milligrams buprenorphine and 4 milligrams of naloxone, bringing a new dosage strength to the market.
Get the full story at our sister site, Drug Delivery Business News.
The post Teva wins FDA nod for sublingual film to treat opioid dependence appeared first on MassDevice. (Source: Mass Device)
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
